Clarivate Unveils 2026 “Drugs to Watch” Report Highlighting 11 Potential Blockbuster and Transformative Therapies

Clarivate Plc, a global leader in transformative intelligence, has released its highly anticipated 2026 Drugs to Watch report, identifying eleven therapies poised to deliver major clinical impact and significant commercial success in the near future. The annual analysis examines treatments across key areas including metabolic diseases, oncology, immunology, neurological disorders and rare conditions, all selected for their potential to either reach blockbuster status—defined as exceeding $1 billion in annual sales—or fundamentally transform patient care within the next five years. The report integrates Clarivate’s advanced, AI‑enhanced datasets—such as Cortellis Competitive Intelligence, Clinical Trials Intelligence, Regulatory Intelligence and more—along with expert analysis to evaluate hundreds of drugs across development stages and global markets. Clarivate’s President of Life Sciences & Healthcare, Henry Levy, emphasized that 2026 will be marked by unprecedented innovation and increasing complexity in the pharmaceutical landscape, with the report not only spotlighting emerging therapies but also broader trends shaping the industry. Among the therapies featured are Orforglipron and Retatrutide from Eli Lilly & Co, advancing treatment options for obesity and type 2 diabetes, and Exdensur (depemokimab) from GSK for asthma. These therapies exemplify the shift toward next‑generation mechanisms, improved delivery methods, and broader indications aimed at improving patient outcomes. The report also underscores the growing role of precision medicine and innovation in drug delivery, as well as the emergence of Mainland China as a key market and source of new therapeutic innovation. #DrugsToWatch #PharmaInnovation #BlockbusterTherapies #HealthcareTrends #SlimScan #GrowthStocks #CANSLIM